Advertisement

Corpuscarcinom

  • Christian Marth
Part of the Onkologie heute book series (ONKOLOGIE)

Zusammenfassung

Das Corpuscarcinom ist mit einer Inzidenz von 28 auf 100.000 Frauen in den industrialisierten Ländern der häufigste genitale Tumor. Unter allen gynäkologischen Carcinomen sowie unter den 10 häufigsten malignen Neoplasien der Frau sind beim Endometriumcarcinom die höchsten Heilungsraten zu erzielen (Rose 1996). Die überwiegende Mehrzahl (ca. 97%) aller bösartiger Tumoren des Corpus uteri sind Carcinome, die aus den Endometriumdrüsen entstehen. Der Rest besteht aus Sarcomen oder gemischten mesodermalen Tumoren (Marth et al. 1997). Eine Vielzahl neuer Erkenntnisse über Entstehung, Prognose und Therapie sowie neue Definitionen der histologischen Typen und des Stadiums machen einen Übersichtsartikel zum Corpuscarcinom notwendig.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathological study of 540 patients. Obstet Gynecol 56: 419–427.PubMedGoogle Scholar
  2. [2]
    Abeler VM, Kjørstad KE (1991) Endometrial adenocarcinoma in Norway. Cancer 67: 3093–3103.PubMedCrossRefGoogle Scholar
  3. [3]
    Abeler VM, Kjørstad KE, Berle E (1992) Carcinoma of the endometrium in Norway: A histopathological and prognostic survey of a total population. Int J Gynecol Oncol 47:207–214.Google Scholar
  4. [4]
    Announcements (1989) FIGO stages: 1988 revision. Gynecol Oncol 35: 125–127.CrossRefGoogle Scholar
  5. [5]
    Atad J, Weill S, Ben-David Y, Hallak M, Lurie O, Abramovici H (1994) Intraoperative frozen section examination of myometrial invasion depth in patients with endometrial cancer. Int J Gynecol Cancer 4: 352–355.PubMedCrossRefGoogle Scholar
  6. [6]
    Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 62: 278–281.PubMedCrossRefGoogle Scholar
  7. [7]
    Benevolo M, Mariani L, Vocaturo G, Vasselli S, Natali PG, Mottolese (2000) Independent prognostic value of peritoneal immunocytodiagnosis in endometrial carcinoma. Am J Surg Pathol 24: 241–247.PubMedCrossRefGoogle Scholar
  8. [8]
    Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast Jr RC (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15–21.PubMedGoogle Scholar
  9. [9]
    Berchuck A (1995) Biomarkers in the endometrium. J Cell Biochem 23: 174–178.CrossRefGoogle Scholar
  10. [10]
    Bergeron C, Nogales FF, Masseroli M, Abeler V, Duvillard P, Müller-Holzner E, Pickartz H, Wells M (1999) A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 23: 1102–1108.PubMedCrossRefGoogle Scholar
  11. [11]
    Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91: 1654–1662.PubMedCrossRefGoogle Scholar
  12. [12]
    Calero F, Asins-Codoner E, Jimeno E, Rodriguez-Escudero F, Mendena J, Iglesias J, Matia F, Armas A, Diaz-Castellanos R, Garzon J (1991) Epirubicin in advanced endometrial adenocarcinoma. Eur J Cancer 27: 864–866.PubMedCrossRefGoogle Scholar
  13. [13]
    Cerin Å, Heldaas K, Møller B (1996) Adverse endometrial effects of long-cycle estrogen and progestagen replacement therapy. N Engl J Med 334: 668–669.PubMedCrossRefGoogle Scholar
  14. [14]
    Cirisano FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL (1999) Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74: 385–394.PubMedCrossRefGoogle Scholar
  15. [15]
    Cornelison TL, Trimble EL, Kosary CL (1999) SEER data, corpus uteri cancer: Treatment trends versus survival for FIGO stage II, 1988–1994. Gyn Oncol 74: 350–355.CrossRefGoogle Scholar
  16. [16]
    Creasman W, Morrow CP, Bundy B, Homesley HD, Graham JE, Heller PB (1987) Surgical pathological spread patterns of endometrial cancer. Cancer 60: 2035 2041.PubMedCrossRefGoogle Scholar
  17. [17]
    Creasman WT (1990) New gynecologic cancer staging. Obstet Gynecol 75: 287–288.PubMedGoogle Scholar
  18. [18]
    Cretzberg CL, van Putten WLJ, Koper PCM, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van de Stehen-Babasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. Lancet 355: 1404–1411.CrossRefGoogle Scholar
  19. [19]
    Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK (1994) Early mutational activation of the c-Ki-ras onkogene in endometrial carcinoma. Cancer Res 54: 1604–1607.PubMedGoogle Scholar
  20. [20]
    Ebina Y, Hareyama H, Sakuragh N, Yamamoto R, Furuya M, Sogame M, Fujino T, Makinoda S, Fujimoto S (1997) Peritoneal cytology and its prognostic value in endometrial carcinoma. Int Surg 82: 244–248.PubMedGoogle Scholar
  21. [21]
    Ehrlich CE, Young PCM, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158: 796–807.PubMedGoogle Scholar
  22. [22]
    Fiorica J, Brunetto V, Hanjani P, Lkentz S, Mannel R, Anderson W (2000) A phase II study (GOG 153) of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate and tamoxifen citrate. Proc Am Soc Clin Oncol 19: 1499.Google Scholar
  23. [23]
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388.PubMedCrossRefGoogle Scholar
  24. [24]
    Fleming GF, Brunetto VL, Bentley R, Raser J, Clarke-Pearson D, Sorosky J, Eaton L, Gallion H, Gibbons WE (2000) Randomized trial of doxorubicin (DOX) plus cisplatin versus DOX plus paclitaxel (TAX) plus granulocyte colony-stimulating factor (G-CSF) in patients with advanced or recurrent endometrial cancer: A report on Gynecologic Oncology Group (GOG) protocol #163. Proc Am Soc Clin Oncol 19: 1498.Google Scholar
  25. [25]
    Fugere P, Scheele WH, Shah A, Strack TR, Glant MD, Jolly E (2000) Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 182: 568–574.PubMedCrossRefGoogle Scholar
  26. [26]
    Gima T, Kato H, Honda T, Imamura T, Sasazuki T, Wake N (1994) DCC gene alteration in human endometrial carcinomas. Int J Cancer 57: 480–485.PubMedCrossRefGoogle Scholar
  27. [27]
    Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95: 95–103.PubMedCrossRefGoogle Scholar
  28. [28]
    Greven K, Olds W (1987) Isolated vaginal recurrences and their management. Cancer 60:419–421.PubMedCrossRefGoogle Scholar
  29. [29]
    Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC (1992) HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179–185.PubMedCrossRefGoogle Scholar
  30. [30]
    Judd HL, Shamonki IM, Frumar AM, Lagasse LD (1986) Origin of serum estradiol in postmenopausal women. Obstet Gynecol 59: 680–686.Google Scholar
  31. [31]
    Kacinski BM, Carter D, Kohorn El, Mittal K, Bloodgood RS, Donahue J, Donofrio L, Edwards R, Schwartz PE (1988) High level expression of fms proto-oncogene mRNA is observed in clinically aggressive endometrial adenocarcinomas. Int J Radiat Oncol BiolPhys 15: 823–829.CrossRefGoogle Scholar
  32. [32]
    Kacinski BM, Chambers S, Stanley E, Carter D, Tseng P, Scata K, Chang D, Pirro MH, Nguyen J, Ariza A, Rohrschneider L, Rothwell V (1990) The cytokine CSF-1 (M-CSF), expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. Int J Radiat Oncol Biol Phys 15: 823–829.CrossRefGoogle Scholar
  33. [33]
    Kadar N, Homesley HD, Malfetano JH (1994) Prognostic factors in surgical stage III and IV carcinoma of the endometrium. Obstet Gynecol 84: 983–986.PubMedGoogle Scholar
  34. [34]
    Kucera H, Vavra N, Weghaupt K (1990) Benefit of external irradiation in pathological stage I endometrial carcinoma: A prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38: 99–104.PubMedCrossRefGoogle Scholar
  35. [35]
    Kurman RJ, Norms HJ (1987) Endometrial carcinoma. In: Blaustein A (ed) Pathology of the Female Genital Tract. Springer, New York, S. 324–351.Google Scholar
  36. [36]
    Lax S, Kendall B, Tashiro H, Slebos RJC, Ellenson LH (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer 88: 814–824.PubMedCrossRefGoogle Scholar
  37. [37]
    Leijon T, Rosenberg P, Boeryd B (1997) Total abdominal hysterectomy and bilateral salpingo-oophorectomy. A sufficient treatment for patients with low risk endometrial carcinoma. Int J Gynecol Cancer 7: 376–380.CrossRefGoogle Scholar
  38. [38]
    Leveque J, Goyat F, Dugast J, Loeillet L, Grall JY, Le Bars S (1998) Value of peritoneal cytology after hysteroscopy in surgical stage I adenocarcinoma of the endometrium. Oncol Rep 5: 713–715.PubMedGoogle Scholar
  39. [39]
    Mariani A, Webb MJ, Galli L, Podratz KC (2000) Potential therapeutic role of paraaortic lymphadenectomy in node-positive endometrial cancer. Gyn Oncol 76: 348–356.CrossRefGoogle Scholar
  40. [40]
    Marth C, Koza A, Müller-Holzner E, Hetzel H, Fuith LC, Dapunt O (1990) Prognostisch relevante Faktoren beim malignen Müllerschen Mischtumor. Geburtshilfe u Frauenheilk 50: 605–609.CrossRefGoogle Scholar
  41. [41]
    Marth C, Dapunt O (1995) Chirurgischer Standard beim Endometriumcarcinom. Gynäkol Geburtsh Rundsch 35: 122–123.CrossRefGoogle Scholar
  42. [42]
    Marth C, Daxenbichler G (1996) Prognostic factors in endometrial cancer. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormones and Cancer. Dekker, New York, S. 499–508.Google Scholar
  43. [43]
    Marth C, Windbichler G, Petru E, Dirschlmayer W, Obermair A, Czerwenka K, Müller-Holzner E, Dapunt O (1997) Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol 64: 121–125.PubMedCrossRefGoogle Scholar
  44. [44]
    Morrow CP, Bundy B, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. Gynecol Oncol 40: 55–65.PubMedCrossRefGoogle Scholar
  45. [45]
    Monk BJ, Chapman JA, Johnsen G, Brightman B, Wilczynski S, Schell MJ, Fan H (1994) Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 171: 1193–1198.PubMedGoogle Scholar
  46. [46]
    Muss H (1994) Chemotherapy of metastatic endometrial cancer. Semin Oncol 21: 107–113.PubMedGoogle Scholar
  47. [47]
    Norris HJ, Connor MP, Kurman RJ (1986) Preinvasive lesions of the endometrium. Clin Obstet Gynecol 13: 725–738.Google Scholar
  48. [48]
    Obermair A, Geranou M, Gücer F, Denison U, Graf AH, Kapshammer E, Medl M, Rosen A, Wierrani F, Neunteufel W, Frech I, Speiser P, Kainz C, Breitenecker G (1999) Endometrial cancer: Accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer 9: 383–386.PubMedCrossRefGoogle Scholar
  49. [49]
    Obermair A, Geranou M, Gücer F, Denison U, Graf AH, Kapshammer E, Neunteufel W, Frech I, Kaider A, Kainz C (2000) Does hysteroscopy facilitate tumor cell dissemination? Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and curettage (D&C) versus hysteroscopy and D&C. Cancer 88: 139–143.PubMedCrossRefGoogle Scholar
  50. [50]
    Odom LD, Barrett J, Pantazis CG, Stoddard L, McDonough P (1989) Immunocytochemical study of ras and myc proto-onkogene polypeptide expression in the human menstrual cycle. Am J Obstet Gynecol 161: 1663–1668.PubMedGoogle Scholar
  51. [51]
    Parazzini F, Negri E, LaVecchia C, Benzi G, Chiaffarino F, Polatti A, Franceschi S (1998) Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 76: 784–786.PubMedCrossRefGoogle Scholar
  52. [52]
    Parslov M, Lidegaard Ø, Klintorp S, Pedersen B, Jønsson L, Eriksen PS, Ottesen B (2000) Risk factors among young women with endometrial cancer: A Danish casecontrol study. Am J Obstet Gynecol 182: 23–29.PubMedCrossRefGoogle Scholar
  53. [53]
    Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT (1998) CA-125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 82: 1720–1725.PubMedCrossRefGoogle Scholar
  54. [54]
    Rose PG (1996) Endometrial carcinoma. N Engl J Med 335: 640–649.PubMedCrossRefGoogle Scholar
  55. [55]
    Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS (1989) Endometrial cancer: Histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 73: 780–785.PubMedGoogle Scholar
  56. [56]
    Seidman J, Kurman RJ (1999) Tamoxifen and the endometrium. Int J Gynecol Pathol 18:293–296.PubMedCrossRefGoogle Scholar
  57. [57]
    Shoff SM, Newcomb (1998) Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 148: 234–240.PubMedCrossRefGoogle Scholar
  58. [58]
    Silverman MB, Roche PC, Kho RM, Keeney GL, Li H, Podratz KC (2000) Molecular and cytogenetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol 77: 1–7.PubMedCrossRefGoogle Scholar
  59. [59]
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin LJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of HER-2/neu proto-onkogen in human breast and ovarian cancer. Science 244: 707–712.PubMedCrossRefGoogle Scholar
  60. [60]
    Sonoda Y, Zerbe M, Barakat RR, Brown CL, Chi DS, Poynor EA, Hoskins WJ (2000) High incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy. Gyn Oncol 76: 235.CrossRefGoogle Scholar
  61. [61]
    Terakawa N, Harada T, Minagawa Y, Kigawa J, Sato B (1996) Endometrial cancer. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormones and Cancer. Dekker, New York, S. 477–498.Google Scholar
  62. [62]
    Thipgen T, Buchsbaum H, Mangan C, Blessing JA (1979) Phase II trial of Adriamycin in the treatment of advanced and recurrent endometrial carcinoma. Cancer Treat Rep 63:21–27.Google Scholar
  63. [63]
    Thipgen T, Vance RB, Khansur T (1995) The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 22: 67–75.Google Scholar
  64. [64]
    Vergote I, Kjørstad K, Abeler V, Kolstad P (1989) A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64: 1011–1016.PubMedCrossRefGoogle Scholar
  65. [65]
    Watson P, Lynch HAT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71: 677–685.PubMedCrossRefGoogle Scholar
  66. [66]
    Webb MJ, Mariani A, Keeney GL, Calori G, Podratz KC (2000) Role of wide/radical hysterectomy and pelvic lymphadenectomy in edometrial cancer with cervical involvement. Gyn Oncol 76: 234–235.Google Scholar
  67. [67]
    Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131–1137.PubMedCrossRefGoogle Scholar
  68. [68]
    Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M (1998) Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: Patterns of relapse and side effects following low-dose therapy. Gyn Oncol 71: 72–76.CrossRefGoogle Scholar
  69. [69]
    Westhoff C, Heller D, Drosinos S, Tancer L (2000) Risk factors for hyperplasia-associated versus atrophy-associated endometrial carcinoma. Am J Obstet Gynecol 182: 506–508.PubMedCrossRefGoogle Scholar
  70. [70]
    Woodruff JD, Pickar JH (1994) Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 170: 1213–1223.PubMedGoogle Scholar
  71. [71]
    Wylie J, Irwin C, Pintilie M, Levin W, Manchul L, Milosevic M, Fyles A (2000) Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 77: 66–72.PubMedCrossRefGoogle Scholar
  72. [72]
    Yokoyama Y, Maruyama H, Sato S, Saito Y (1997) Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 64: 411–417.PubMedCrossRefGoogle Scholar
  73. [73]
    Zaino RJ, Silverberg SG, Norris HJ, Bundy BN, Morrow CP, Okagaki T (1994) The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: A Gynecologic Oncology Group study. Int J Gynecol Pathol 13: 29–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Christian Marth
    • 1
  1. 1.Universitätsklinik für FrauenheilkundeInnsbruckÖsterreich

Personalised recommendations